• S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia

  • Nov 15 2023
  • Length: 34 mins
  • Podcast
S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia By cover art

S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia

Listen for free

View show details

  • Summary

  • FLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how they are used in AML, and how to manage any treatment-related adverse events.

    Visit www.morningcommutepodcast.com/aml4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    Show more Show less
Show more Show less

What listeners say about S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available